retatrutide clinical trials phase 3 obesity trial just came out and the results are genuinely insane: - 28.3% bodyweight lost on 12mg over 80 weeks Eli Lilly's Phase 3 data

Teens who participated experienced 16% total body weight loss at 68 weeks while taking semaglutide

Individuals in Miami Beach seeking information on who can prescribe Zepbound will find that it is not recommended for those with a history of medullary thyroid cancer, severe gastrointestinal disease, or pancreatitis

Ongoing safety depends on patient self-reporting through messaging and follow-up visits

K.FaigleM.KnappS.KarhausenJ.IblaJ.RosenbergerP.et al (2006)

If Evolv produces comparable weight loss orally, it would be a significant advancement

[19] The gut is compromised in celiac disease, and this can cause reduced nutrient absorption, including iron absorption